Kornitzer Capital Management Inc. KS Has $4.01 Million Stock Position in Novo Nordisk A/S $NVO

Kornitzer Capital Management Inc. KS lowered its position in Novo Nordisk A/S (NYSE:NVO) by 35.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 109,092 shares of the company’s stock after selling 59,053 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Novo Nordisk A/S were worth $4,009,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Boston Partners acquired a new position in shares of Novo Nordisk A/S in the third quarter valued at $310,199,000. Price T Rowe Associates Inc. MD boosted its stake in Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after buying an additional 4,836,285 shares in the last quarter. Voloridge Investment Management LLC increased its holdings in Novo Nordisk A/S by 851.6% in the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after buying an additional 4,302,126 shares during the period. Bank of Montreal Can increased its holdings in Novo Nordisk A/S by 138.9% in the 4th quarter. Bank of Montreal Can now owns 2,525,827 shares of the company’s stock valued at $128,514,000 after buying an additional 1,468,409 shares during the period. Finally, Quadrature Capital Ltd acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $59,882,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NVO shares. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Sanford C. Bernstein began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 target price on the stock. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Finally, Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Five research analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s Wegovy access continues to expand, and a recent U.K. approval has added to optimism around demand for its GLP-1 franchise, supporting the stock’s recent rebound. Article Title
• Positive Sentiment: The company launched Awiqli, the world’s first once-weekly basal insulin, in India, a move that could strengthen Novo Nordisk’s diabetes footprint in a large and fast-growing market. Article Title
• Positive Sentiment: Analysts and commentators continue to argue that the stock still has a long-term bull case, with some saying the decline from highs has made the valuation more attractive relative to the company’s growth prospects. Article Title
• Neutral Sentiment: Several articles note that investors are simply watching Novo Nordisk more closely, suggesting heightened interest rather than a single new fundamental catalyst. Article Title
• Neutral Sentiment: Coverage around a Wegovy label update and broader GLP-1 enthusiasm is keeping the name in focus, but the market appears to be balancing this against the risk that competition and earnings pressure could limit upside. Article Title
• Negative Sentiment: Recent commentary also highlights rising competition in the obesity and diabetes drug markets, which could pressure Novo Nordisk’s growth and margins over time. Article Title
• Negative Sentiment: One recent market note said NVO has been slipping relative to the broader market, reflecting some near-term profit taking after the stock’s strong run. Article Title

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded up $0.61 on Friday, hitting $49.49. The stock had a trading volume of 6,314,361 shares, compared to its average volume of 10,696,942. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $71.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The firm’s 50 day moving average price is $45.57 and its 200-day moving average price is $45.87. The company has a market capitalization of $220.96 billion, a price-to-earnings ratio of 11.62, a price-to-earnings-growth ratio of 4.51 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.